Janumet Contraindications

JANUMET (sitagliptin phosphate/metformin HCl) is contraindicated in patients with: Severe renal failure (GFR < 30 mL/min) (see Dosage & Administration and Precautions): acute conditions with the potential to alter renal function such as: dehydration, severe infection, shock.
Known hypersensitivity to sitagliptin phosphate, metformin hydrochloride or any other component of JANUMET (see Sitagliptin phosphate: Hypersensitivity Reactions under Precautions; Postmarketing Experience under Side Effects).
Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.
JANUMET should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because the use of such products may result in acute alteration of renal function (see Metformin hydrochloride: Radiologic studies involving the use of intravascular iodinated contrast materials (for example, intravenous urogram, intravenous cholangiography, angiography, and computed tomography (CT) scans with intravascular contrast materials) under Precautions).